African Pharmaceutical Review.

African Pharmaceutical Review.

Pharverse
Trending
SAHPRA signs MoU with Rwanda Food and Drug Authority
Bristol Myers Squibb’s Zeposia exhibits sustained safety and efficacy in Multiple sclerosis
WHO prequalifies diagnostic test to minimize hemolysis from antimalarial drugs

R&D

View All
Injectable drug shows 99.9% efficacy in HIV prevention

Injectable drug shows 99.9% efficacy in HIV prevention

AstraZeneca’s first in class therapy shows efficacy in metastatic prostate cancer

AstraZeneca’s first in class therapy shows efficacy in metastatic prostate cancer

FDA accepts for review GSK’s new multiple myeloma therapy

FDA accepts for review GSK’s new multiple myeloma therapy

Drug shows reduced risk of progression to type 2 diabetes in pre-diabetics

Drug shows reduced risk of progression to type 2 diabetes in pre-diabetics

Selumetinib shows efficacy in adult patients with neurofibromatosis

Selumetinib shows efficacy in adult patients with neurofibromatosis

AbbVie’s emraclidine fails to demonstrate efficacy in management of schizophrenia

AbbVie’s emraclidine fails to demonstrate efficacy in management of schizophrenia

Anti-asthmatic therapy shows efficacy in treatment of chronic rhinosinusitis with nasal polyps

Anti-asthmatic therapy shows efficacy in treatment of chronic rhinosinusitis with nasal polyps

Regeneron’s dupilumab has achieved approval in Europe as the first treatment approved for children with eosinophilic esophagitis

Regeneron’s dupilumab has achieved approval in Europe as the first treatment approved for children with eosinophilic esophagitis

GSK acquires new investigational therapy targeted for lupus treatment

GSK acquires new investigational therapy targeted for lupus treatment

AstraZeneca’s brand of benralizumab gains approval in Europe

AstraZeneca’s brand of benralizumab gains approval in Europe

Oral semaglutide shows reduction in risk of major adverse cardiovascular events in diabetic patients

Oral semaglutide shows reduction in risk of major adverse cardiovascular events in diabetic patients

First once-daily subcutaneous prophylactic treatment for hemophilia recommended for European approval

First once-daily subcutaneous prophylactic treatment for hemophilia recommended for European approval

Innovative subcutaneous combination therapy receives approval for Parkinson's disease

Innovative subcutaneous combination therapy receives approval for Parkinson's disease

GSK’s first-in-class antibiotic with new mechanism of action approved for priority review

GSK’s first-in-class antibiotic with new mechanism of action approved for priority review

AstraZeneca to pay up to $1.92 billion for potentially new lipid lowering molecule

AstraZeneca to pay up to $1.92 billion for potentially new lipid lowering molecule

FDA approves drug with new pharmacological approach to schizophrenia treatment

FDA approves drug with new pharmacological approach to schizophrenia treatment

AstraZeneca’s Fasenra set to be approved for eosinophilic granulomatosis treatment

AstraZeneca’s Fasenra set to be approved for eosinophilic granulomatosis treatment

Novo Nordisk’s Wegovy® expects label update to include benefits in improving heart failure symptoms and physical function.

Novo Nordisk’s Wegovy® expects label update to include benefits in improving heart failure symptoms and physical function.

Roche’s Xofluza reduces transmission of flu viruses, global trial shows

Roche’s Xofluza reduces transmission of flu viruses, global trial shows

Bristol Myers Squibb’s Zeposia exhibits sustained safety and efficacy in Multiple sclerosis

Bristol Myers Squibb’s Zeposia exhibits sustained safety and efficacy in Multiple sclerosis

Novartis Kisqali® has received FDA approval to lower recurrence risk in patients with HR+/HER2-early breast cancer.

Novartis Kisqali® has received FDA approval to lower recurrence risk in patients with HR+/HER2-early breast cancer.

Research shows 2-drug HIV regimen with comparable efficacy to 3-drug regimen

Research shows 2-drug HIV regimen with comparable efficacy to 3-drug regimen

Disrupting and accelerating drug discovery for faster and more accurate lead identification

Disrupting and accelerating drug discovery for faster and more accurate lead identification